Shares of Cassava Sciences (NASDAQ: SAVA) jumped by as much as 26% in pre-market trading Friday morning. The pre-revenue biotech's stock took flight after a positive note from investment bank Cantor Fitzgerald.
Specifically, Cantor Fitzgerald set a $24 per share price target on the biotech's stock Thursday after the closing bell. For those of you keeping score at home, that implies a whopping 172% upside potential from the $8.83 level where Cassava's shares closed on Thursday.
Image source: Getty Images.
For further details see:
Why Cassava Sciences Is Bolting Higher Today